158 related articles for article (PubMed ID: 105805)
1. Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents.
Bonomi PD; Mladineo J; Morrin B; Wilbanks G; Slayton RE
Cancer Treat Rep; 1979 Jan; 63(1):137-8. PubMed ID: 105805
[No Abstract] [Full Text] [Related]
2. Evaluation of a hexamethylmelamine and 5-fluorouracil combination in the treatment of advanced ovarian carcinoma.
Kardinal CG; Luce JK
Cancer Treat Rep; 1977 Dec; 61(9):1691-3. PubMed ID: 413624
[TBL] [Abstract][Full Text] [Related]
3. Phae II study of hexamethylmelamine in women with advanced breast cancer refractory to standard cytotoxic therapy.
Denefrio JM; Vogel CL
Cancer Treat Rep; 1978 Jan; 62(1):173-5. PubMed ID: 414835
[No Abstract] [Full Text] [Related]
4. Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma.
Johnson BL; Fisher RI; Bender RA; DeVita VT; Chabner BA; Young RC
Cancer; 1978 Nov; 42(5):2157-61. PubMed ID: 102417
[TBL] [Abstract][Full Text] [Related]
5. Phase I--II study of hexamethylmelamine plus dibromodulcitol in refractory carcinoma of the breast.
Van Amburg AL; Presant CA; Vélez-García E; Klahr C
Cancer Treat Rep; 1979 Jan; 63(1):141-2. PubMed ID: 105806
[No Abstract] [Full Text] [Related]
6. Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?
Foster BJ; Clagett-Carr K; Marsoni S; Simon R; Leyland-Jones B
Cancer Treat Rep; 1986 Aug; 70(8):1003-14. PubMed ID: 3089597
[TBL] [Abstract][Full Text] [Related]
7. "Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?".
Bruckner HW
Cancer Treat Rep; 1987 Jun; 71(6):666-8. PubMed ID: 3107816
[No Abstract] [Full Text] [Related]
8. Randomized phase II trial of hexamethylmelamine versus pentamethylmelamine in carcinoma of the bilharzial bladder.
Gad-el-Mawla N; Ziegler JL; Hamza R; Elserafi M; Khaled H
Cancer Treat Rep; 1984 May; 68(5):793-4. PubMed ID: 6426792
[No Abstract] [Full Text] [Related]
9. Chemotherapeutic management of carcinoma of the bilharzial bladder: a phase II trial with hexamethylmelamine and VM-26.
Gad-el-Mawla NM; Muggia FM; Hamza MR; El-Morsi B; Sherif M; Mansour MA; Khafagy M; El-Sebai IT
Cancer Treat Rep; 1978 Jul; 62(7):993-6. PubMed ID: 99234
[No Abstract] [Full Text] [Related]
10. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.
Markman M; Blessing JA; Moore D; Ball H; Lentz SS
Gynecol Oncol; 1998 Jun; 69(3):226-9. PubMed ID: 9648592
[TBL] [Abstract][Full Text] [Related]
11. Hexamethylmelamine in mustard-resistant ovarian adenocarcinoma.
Omura GA; Greco FA; Birch R
Cancer Treat Rep; 1981; 65(5-6):530-1. PubMed ID: 6786741
[No Abstract] [Full Text] [Related]
12. The role of hexamethylmelamine in advanced ovarian carcinoma treatment.
Weiss RB
Gynecol Oncol; 1981 Oct; 12(2 Pt 1):141-9. PubMed ID: 6795094
[No Abstract] [Full Text] [Related]
13. Phase I trial of pentamethylmelamine.
Ajani JA; Cabanillas FF; Bodey GP
Cancer Treat Rep; 1982 May; 66(5):1227-8. PubMed ID: 6805950
[TBL] [Abstract][Full Text] [Related]
14. Phase II evaluation of hexamethylmelamine in advanced breast cancer: a Southwest Oncology Group study.
Fabian CJ; Rasmussen S; Stephens R; Haut A; Smith F; Balcerzak S; Tranum B
Cancer Treat Rep; 1979 Aug; 63(8):1359-61. PubMed ID: 113095
[TBL] [Abstract][Full Text] [Related]
15. Hexamethylmelamine, vincristine, and methotrexate chemotherapy in advanced neoplasms.
Longacre D; Donavan M; Paladine W; Cunningham T; Sponzo R
Cancer Treat Rep; 1977 Aug; 61(5):919-22. PubMed ID: 408004
[No Abstract] [Full Text] [Related]
16. Phase II trial of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian carcinoma.
Kane R; Harvey H; Andrews T; Bernath A; Curry S; Dixon R; Gottlieb R; Kukrika M; Lipton A; Mortel R; Ricci J; White D
Cancer Treat Rep; 1979 Feb; 63(2):307-9. PubMed ID: 109201
[TBL] [Abstract][Full Text] [Related]
17. [Combination chemotherapy with hexamethylamine (Hexalen, Altretamine, Hexastat) and sarcolysine in advanced ovarian carcinoma].
Gershanovich ML; Livshits ME; Antipenkova VI
Vopr Onkol; 2000; 46(5):604-7. PubMed ID: 11202196
[TBL] [Abstract][Full Text] [Related]
18. Hexamethylmelamine. An evaluation of its role in the therapy of cancer.
Legha SS; Slavik M; Carter SK
Cancer; 1976 Jul; 38(1):27-35. PubMed ID: 820422
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of hexamethylmelamine for disseminated prostatic carcinoma.
Drelichman A; Brownlee R; Al-Sarraf M
Cancer Clin Trials; 1981; 4(3):309-12. PubMed ID: 6793256
[TBL] [Abstract][Full Text] [Related]
20. Preliminary report on the use of CCNU (NSC-79037), adriamycin (NSC-123127), and hexamethylmelamine (NSC-13875) in carcinoma of the lung.
Wilson WL; Andrews NC; Frelick RW; Nealon TF; Bick RL; Adams T
Cancer Treat Rep; 1976 Mar; 60(3):269-71. PubMed ID: 816467
[No Abstract] [Full Text] [Related]
[Next] [New Search]